Skip to main content

See also:

First Hemophilia A treatment designed to reduce frequency of bleeding approved

Tsarevich Alexei Nikolayevich,
Wikicommons (Public Domains tag)

Eloctate Antihemophilic, the first Hemophilia A treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding, has just received FDA approval for treatment of both adults and children who have Hemophilia A. Eloctate is the first Hemophilia. The drug, which consists of the Coagulation Factor VIII molecule (historically known as Antihemophilic Factor) tied to a protein fragment, Fc, which is found in antibodies. This makes the product last longer in the patient’s blood.
Hemophilia A is an inherited, blood clotting disorder, which primarily affects 1 in every 5,000 males born in the US (although it can occur in some females), and is caused by defects in the Factor VIII gene. Patients with the disorder often experience serious bleeding in their joints, as well as muscles, digestive tract and sometimes the brain.

“The approval of this product provides an additional therapeutic option for use in the care of patients with Hemophilia A,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research.

Note: One of the most famous hemophiliacs in history was Tsarevich Alexei Nikolayevich, son of Nicholas Alexandra, who inherited the defective gene through his mother, a granddaughter of Queen Victoria and member of the Hesse-Darmstadt dynasty, which was known to pass it on through its line. In fact, Victoria had passed it on to her daughters Beatrice and Alice (Alexandra’s mother). Alexandra’s brother Frederick had died from hemophilia when he was just 3-years old.